Cidara Therapeutics

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 14.58% and -32.14%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Cidara Therapeutics (CDTX) Reports Q3 Loss, Misses Revenue Estimates

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended September 30, 2020, and provided an update on its corporate activities.

Cidara Provides Corporate Update and Reports Third Quarter 2020 Financial Results

Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Cidara Therapeutics (CDTX) to Report a Decline in Earnings: What to Look Out for

Presentations highlight clinical and preclinical progress of long-acting drug candidates for serious fungal and viral infections

Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020

SAN DIEGO, Sept.  14, 2020  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present two oral abstracts and seven posters at IDWeek 2020, the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medical Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS) and the Society of Infectious Diseases Pharmacists (SIDP), which takes place virtually Oct. 21-25, 2020.

Cidara Therapeutics to Present New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020

SAN DIEGO, Aug.  13, 2020  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended June 30, 2020, and provided an update on its corporate activities and product pipeline.

Cidara Provides Corporate Update and Reports Second Quarter 2020 Financial Results

SAN DIEGO, Aug.  04, 2020  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020.

Cidara Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO, July  17, 2020  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the B. Riley FBR Virtual Summer Series panel on antiviral therapeutics on Tuesday, July 21, 2020.

Cidara Therapeutics to Participate in B. Riley Virtual Summer Series Panel on Antiviral Therapeutics

SAN DIEGO, June  29, 2020  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that it has been added to the Russell 3000® Index at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open today, June 29, 2020.

Cidara Therapeutics Added to Russell 3000® Index

SAN DIEGO, June  23, 2020  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Cantor Fitzgerald “Winning Ways to Treat Infections and COVID-19” Virtual Symposium on Tuesday, June 30, 2020.

Cidara Therapeutics to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19

SAN DIEGO, June  11, 2020  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present virtually at the Raymond James Human Health Innovations Conference on Thursday, June 18, 2020.

Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference

SAN DIEGO and CAMBRIDGE, England, May  20, 2020  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -35.29% and -49.40%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Cidara Therapeutics (CDTX) Reports Q1 Loss, Misses Revenue Estimates

SAN DIEGO, May  13, 2020  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended March 31, 2020, and provided an update on its corporate activities and product pipeline.

Cidara Provides Corporate Update and Reports First Quarter 2020 Financial Results

Abstract Book highlights new data from Cidara accepted for presentation at ECCMID 2020

Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Cidara Therapeutics (CDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

What Makes Cidara Therapeutics (CDTX) a New Strong Buy Stock

Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Cidara Therapeutics (CDTX) a New Buy Stock

Cidara Therapeutics (CDTX) Upgraded to Buy: What Does It Mean for the Stock?

SAN DIEGO, Feb.  18, 2020  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapeutics to improve the standard of care for patients facing severe fungal or viral infections, today announced that it will present a poster at the Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR), which takes place from Feb. 19-23, 2020, in Orlando, Florida. In addition, the Company will have an oral presentation at Mycology 2020, which takes place from Mar. 13-14, 2020, in London.

Cidara Therapeutics to Present at Transplantation & Cellular Therapy (TCT) and Mycology 2020 Medical Conferences

SAN DIEGO, Feb.  12, 2020  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”) today announced the closing of its previously announced rights offering (the “Rights Offering”). At the closing, Cidara sold and issued an aggregate of 6,639,307 shares of its common stock (the “Common Stock”) and an aggregate of 531,288 shares of its Series X convertible preferred stock (“Series X Preferred Stock”), pursuant to the exercise of subscription rights in the Rights Offering from its existing holders of Common Stock, Series X Preferred Stock and Cidara’s warrants issued on May 21, 2018.  Of the total shares of Common Stock and Series X Preferred Stock sold and issued in the Rights Offering, BVF Partners L.P., a Cidara stockholder and warrant holder, purchased 587,244 shares of Common Stock and 531,288 shares of Series X Preferred Stock and Stonepine Capital, LP, a Cidara warrant holder, purchased 1,554,050 shares of Common Stock, pursuant to the exercise of their subscription and oversubscription rights. Cidara raised aggregate gross proceeds of approximately $30.0 million.

Cidara Therapeutics Announces Closing of Rights Offering

SAN DIEGO, Jan.  22, 2020  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”) today commenced the previously announced rights offering to raise gross proceeds of approximately $30.0 million (the “Rights Offering”). Under the terms of the Rights Offering, the holders, as of 5:00 p.m., New York time, on January 21, 2020, of Cidara’s common stock and Series X convertible preferred stock, and Cidara’s warrants issued on May 21, 2018,  are entitled to purchase up to 11,952,191 shares of common stock in the aggregate at a subscription price equal to $2.51 per share, or under certain circumstances, shares of non-voting Series X convertible preferred stock in lieu of common stock (collectively, the “Offered Shares”), as more fully described in the prospectus supplement, dated January 22, 2020, relating to the Rights Offering.

Cidara Therapeutics Announces Commencement of Rights Offering

Callon Petroleum

Kadmon Hlds

NexTier Oilfield Solutions Inc

Ovid Therapeutics

QEP Resources

No matter what, investors are always after returns. These six cheap stocks can make those returns a reality in 2020.

6 Cheap Stocks to Buy Under $7

Rights Offering will be available to all stockholders and 2018 warrant holders of record on January 21, 2020

Cidara Therapeutics Announces Proposed Rights Offering

Employee feedback places Cidara among top small companies in the area Employee feedback places Cidara among top small companies in the area

Cidara Therapeutics Named a San Diego Metro Area Top Workplace for the Third Consecutive Year

SAN DIEGO, Oct.  03, 2019  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present three posters at the Infectious Diseases Society of America (IDSA) IDWeek 2019, which takes place October 2-6, 2019, in Washington, D.C., and four posters, including a late-breaking poster, at the 9th Trends in Medical Mycology (TIMM), which takes place October 11-14, 2019, in Nice, France.

News for Cidara Therapeutics Stock (CDTX)